Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-05-04 @ 3:20 PM
Study NCT ID:
NCT07365904
Status:
RECRUITING
Last Update Posted:
2026-01-26
First Post:
2025-09-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Investigating Ovulation Inhibition for Use as a Contraceptive
Sponsor:
Mylan Pharmaceuticals Inc
Organization:
Study Overview
Official Title:
A Single-centre, Open-label, Phase II Study on the Maintenance of Ovulation Inhibition After Intentional Application Contraceptive
Status:
RECRUITING
Status Verified Date:
2026-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
Detailed Description:
Ovulation inhibition study of MR-130A-01 contraceptive transdermal patch containing norelgestromin with intentional application errors; MR-130A-01-TD-2002
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: